相关实验视频

Updated: Jun 8, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

一个基于血液的生物标志物小组用于非侵入性诊断代谢功能障碍相关的脂肪肝炎

Xiang Zhang¹, Ming-Hua Zheng², Dehua Liu¹

¹Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shenzhen Research Institute, Hong Kong SAR, China.

Cell metabolism

|November 5, 2024

概括

一个新的血液测试面板,N3-MASH,有助于诊断代谢功能障碍相关的脂肪肝炎 (MASH). 这种非侵入性方法对识别MASH和监测治疗反应具有前景,可能减少肝脏活检的需要.

科学领域:

肝病学肝病学是一种肝病学.
生物标志物发现发现
诊断发展诊断发展

背景情况:

目前对代谢功能障碍相关的脂肪性肝病 (MASLD) 和其严重形式,代谢功能障碍相关的脂肪性肝炎 (MASH) 的诊断是不理想的.
需要准确和非侵入性诊断工具来有效管理MASLD和MASH.

研究的目的:

开发和验证MASH的非侵入性诊断面板.
评估小组能够将MASLD与健康对照区分开来,并在MASLD人群中识别MASH的能力.
评估面板在识别MASH改进方面的实用性.

主要方法:

在发现和验证队伍中招募了700名个人.
制定了一个诊断面板 (N3-MASH),包括C-X-C动机化学因联体10 (CXCL10),细胞克拉18片段M30 (CK-18) 和调整的体重指数 (BMI).
使用接收器操作特征 (AUROC) 曲线下的面积来评估诊断性能.

主要成果:

N3-MASH将MASLD与健康对照进行了歧视,AUROC为0.954.
在MASLD患者中,N3-MASH确定了MASH,AUROC为0.823 (90.0%的特异性,62.9%的灵敏度).
该小组的表现在三个队列中得到验证 (AUROCs 0.802-0.823) 并显示AUROC为0.857以确定MASH改进.

结论:

一个强大的,基于血液的N3-MASH面板使MASH的非侵入性诊断成为可能.
这个小组可以帮助临床医生识别MASH和监测治疗,从而减少肝脏活检的需要.

关键词:

马什 (MASH) 是一个非常重要的产品.马斯尔德马斯尔德是什么意思这就是N3-MASH.诊断诊断诊断诊断诊断诊断标记器标记器标记器多个队列多个队列.这是一种非侵入性的非侵入性治疗方法.血液中的血清是血清.

更多相关视频

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Serum Laboratory Studies, Stool Test, Breath Test

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):